Cancer Trial Tests Novel Immune Booster BAY 2416964 With Pembrolizumab
Researchers tested a new drug combination targeting immune suppression in advanced solid tumors before early termination.
Summary
Researchers investigated BAY 2416964, a novel drug that blocks the Aryl Hydrocarbon Receptor (AhR) protein, combined with pembrolizumab immunotherapy for advanced solid cancers. The AhR protein can prevent immune cells from attacking tumors, so blocking it may enhance the body's natural cancer-fighting response. This phase 1 trial enrolled 47 participants with head and neck, lung, and bladder cancers to determine the safest effective dose and evaluate how well the combination works. The study used a two-part design: first finding the optimal dose, then testing it in more patients. However, the trial was terminated early, though specific reasons weren't provided in the available data.
Detailed Summary
Bayer conducted a phase 1 clinical trial investigating BAY 2416964, an innovative small molecule that blocks the Aryl Hydrocarbon Receptor (AhR), combined with pembrolizumab immunotherapy for treating advanced solid tumors. The AhR protein can suppress immune system function, preventing the body's natural defenses from effectively attacking cancer cells.
The study enrolled 47 participants with advanced head and neck, lung, and bladder cancers. Researchers designed a two-phase approach: dose escalation to find the maximum tolerated dose, followed by dose expansion to test efficacy. Participants received oral BAY 2416964 daily plus intravenous pembrolizumab in 21-day cycles until disease progression or unacceptable toxicity.
The trial's primary objectives focused on safety, tolerability, and determining the optimal dosing strategy. Secondary endpoints included measuring anti-cancer activity and understanding how the drug combination moves through the body. Participants underwent regular blood tests, imaging scans, and health assessments throughout treatment.
Unfortunately, the trial was terminated early, though the specific reasons weren't detailed in available information. This early termination limits the ability to draw definitive conclusions about the combination's effectiveness or safety profile.
The research represents an important approach to cancer treatment by targeting immune suppression mechanisms. While this particular combination didn't advance to completion, the concept of blocking AhR to enhance immune function remains relevant for future cancer immunotherapy development and potentially other age-related diseases involving immune dysfunction.
Key Findings
- Trial tested novel AhR inhibitor BAY 2416964 to boost immune response against cancer
- Study enrolled 47 patients with advanced head, neck, lung, and bladder cancers
- Two-phase design aimed to find optimal dosing before efficacy testing
- Trial terminated early, limiting conclusions about safety and effectiveness
Methodology
Phase 1 dose-escalation trial with 47 participants over approximately 3.5 years. Two-part design: dose escalation followed by expansion phase using 21-day treatment cycles.
Study Limitations
Early termination prevents definitive safety and efficacy conclusions. Small sample size and lack of disclosed termination reasons limit generalizability and understanding of the approach's viability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.